euro adhoc: Schering AG / Mergers - Acquisitions - Takeovers / Bayer offer remains unchanged despite voluntary Ultravist® Injection 370 mgI/ml recall and insufficient results of clinical Phase III trial with sargramostim (n.o.v.e.l. 4) Executive Board o
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 31.07.2006 Schering AG, Germany is voluntarily recalling its X-ray contrast agent Ultravist Injection 370 mgI/mL (iopromide injection) due to the potential that particulate matter in conjunction ...